• IDEXX Laboratories (NasdaqGS:IDXX) has integrated the SDMA kidney biomarker into its most widely used Catalyst in-clinic chemistry profiles.
• The update allows veterinarians in the US and Canada to detect kidney disease in pets earlier through routine bloodwork.
• Clinics can access SDMA testing without changing existing workflows or investing in separate assays.
• The move aligns the Catalyst platform with international veterinary kidney disease guidelines.

IDEXX Laboratories focuses on veterinary diagnostics and software tools used in everyday clinical practice. By adding SDMA into existing Catalyst chemistry profiles, the company is using its installed base to expand access to kidney monitoring that fits into current testing habits.

For investors looking at NasdaqGS:IDXX, this product update highlights how new biomarkers can be layered onto existing analyzers rather than requiring fresh hardware rollouts. It also provides a development to follow as clinics incorporate guideline-based kidney screening into standard in-clinic panels over time.

Stay updated on the most important news stories for IDEXX Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on IDEXX Laboratories.

Quick Assessment

• ✅ Price vs Analyst Target: At US$546.49, the stock trades about 23% below the US$709.14 analyst price target.
• ⚖️ Simply Wall St Valuation: Simply Wall St views the shares as trading close to estimated fair value.
• ❌ Recent Momentum: The stock is down 7.3% over the past 30 days.

There is only one way to know the right time to buy, sell or hold IDEXX Laboratories. Head to Simply Wall St's company report for the latest analysis of IDEXX Laboratories's Fair Value.

Key Considerations

• 📊 SDMA integration into Catalyst profiles reinforces in-clinic testing as a core part of the business and may deepen ties with veterinarians.
• 📊 Watch how quickly SDMA adoption grows in routine panels, and track any commentary on test volumes and recurring diagnostics revenue.
• ⚠️ With a P/E of about 39x against a medical equipment industry average near 25x, sentiment may be sensitive to any slowdown in utilization or new product uptake.

Dig Deeper

For the full picture including more risks and rewards, check out the complete IDEXX Laboratories analysis. Alternatively, you can check out the community page for IDEXX Laboratories to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.